152 related articles for article (PubMed ID: 9587129)
1. Systemic chemotherapy alone for patients with non-acquired immunodeficiency syndrome-related central nervous system lymphoma: a pilot study of the BOMES protocol.
Cheng AL; Yeh KH; Uen WC; Hung RL; Liu MY; Wang CH
Cancer; 1998 May; 82(10):1946-51. PubMed ID: 9587129
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of non-Hodgkin's lymphoma of the central nervous system with BMPD chemotherapy followed by radiotherapy.
Korfel A; Thiel E
Leuk Lymphoma; 1998 Aug; 30(5-6):609-17. PubMed ID: 9711923
[TBL] [Abstract][Full Text] [Related]
3. Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy. French-Italian Cooperative Group.
Gisselbrecht C; Oksenhendler E; Tirelli U; Lepage E; Gabarre J; Farcet JP; Gastaldi R; Coiffier B; Thyss A; Raphael M
Am J Med; 1993 Aug; 95(2):188-96. PubMed ID: 7689296
[TBL] [Abstract][Full Text] [Related]
4. Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients.
Ferreri AJ; Reni M; Dell'Oro S; Ciceri F; Bernardi M; Camba L; Ponzoni M; Terreni MR; Tomirotti M; Spina M; Villa E
Oncology; 2001; 60(2):134-40. PubMed ID: 11244328
[TBL] [Abstract][Full Text] [Related]
5. High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma.
Alvarnas JC; Negrin RS; Horning SJ; Hu WW; Long GD; Schriber JR; Stockerl-Goldstein K; Tierney K; Wong R; Blume KG; Chao NJ
Biol Blood Marrow Transplant; 2000; 6(3A):352-8. PubMed ID: 10905773
[TBL] [Abstract][Full Text] [Related]
6. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962.
Poortmans PM; Kluin-Nelemans HC; Haaxma-Reiche H; Van't Veer M; Hansen M; Soubeyran P; Taphoorn M; Thomas J; Van den Bent M; Fickers M; Van Imhoff G; Rozewicz C; Teodorovic I; van Glabbeke M;
J Clin Oncol; 2003 Dec; 21(24):4483-8. PubMed ID: 14597741
[TBL] [Abstract][Full Text] [Related]
7. Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors.
Bessell EM; Graus F; Lopez-Guillermo A; Lewis SA; Villa S; Verger E; Petit J
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):501-8. PubMed ID: 15145169
[TBL] [Abstract][Full Text] [Related]
8. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
Abrey LE; Moskowitz CH; Mason WP; Crump M; Stewart D; Forsyth P; Paleologos N; Correa DD; Anderson ND; Caron D; Zelenetz A; Nimer SD; DeAngelis LM
J Clin Oncol; 2003 Nov; 21(22):4151-6. PubMed ID: 14615443
[TBL] [Abstract][Full Text] [Related]
9. Intensive weekly combination chemotherapy for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma.
Sweetenham JW; Mead GM; Whitehouse JM
J Clin Oncol; 1991 Dec; 9(12):2202-9. PubMed ID: 1720454
[TBL] [Abstract][Full Text] [Related]
10. Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.
Rigacci L; Carrai V; Nassi L; Alterini R; Longo G; Bernardi F; Bosi A
Cancer; 2005 Mar; 103(5):970-7. PubMed ID: 15666323
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma.
Sandor V; Stark-Vancs V; Pearson D; Nussenblat R; Whitcup SM; Brouwers P; Patronas N; Heiss J; Jaffe E; deSmet M; Kohler D; Simon R; Wittes R
J Clin Oncol; 1998 Sep; 16(9):3000-6. PubMed ID: 9738568
[TBL] [Abstract][Full Text] [Related]
12. Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. A prospective multi-institutional trial.
Levine AM; Wernz JC; Kaplan L; Rodman N; Cohen P; Metroka C; Bennett JM; Rarick MU; Walsh C; Kahn J
JAMA; 1991 Jul; 266(1):84-8. PubMed ID: 1710673
[TBL] [Abstract][Full Text] [Related]
13. Low dose methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone with zalcitabine in patients with acquired immunodeficiency syndrome-related lymphoma. Effect on human immunodeficiency virus and serum interleukin-6 levels over time.
Levine AM; Tulpule A; Espina B; Boswell W; Buckley J; Rasheed S; Stain S; Parker J; Nathwani B; Gill PS
Cancer; 1996 Aug; 78(3):517-26. PubMed ID: 8697399
[TBL] [Abstract][Full Text] [Related]
14. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
Longo DL; DeVita VT; Duffey PL; Wesley MN; Ihde DC; Hubbard SM; Gilliom M; Jaffe ES; Cossman J; Fisher RI
J Clin Oncol; 1991 Jan; 9(1):25-38. PubMed ID: 1702144
[TBL] [Abstract][Full Text] [Related]
15. Primary T cell leptomeningeal lymphoma--successful treatment with systemic chemotherapy.
Yeh KH; Cheng AL; Tien HF
Oncology; 1995; 52(6):501-4. PubMed ID: 7478439
[TBL] [Abstract][Full Text] [Related]
16. PROMACE-MOPP and intrathecal chemotherapy for CNS lymphomas.
Dent S; Eapen L; Girard A; Hugenholtz H; DaSilva V; Stewart DJ
J Neurooncol; 1996 Apr; 28(1):25-30. PubMed ID: 8740588
[TBL] [Abstract][Full Text] [Related]
17. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments.
Bessell EM; López-Guillermo A; Villá S; Verger E; Nomdedeu B; Petit J; Byrne P; Montserrat E; Graus F
J Clin Oncol; 2002 Jan; 20(1):231-6. PubMed ID: 11773174
[TBL] [Abstract][Full Text] [Related]
18. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
19. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
[TBL] [Abstract][Full Text] [Related]
20. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma.
Stoppa AM; Bouabdallah R; Chabannon C; Novakovitch G; Vey N; Camerlo J; Blaise D; Xerri L; Resbeut M; Di Stefano D; Bardou VJ; Gastaut JA; Maraninchi D
J Clin Oncol; 1997 May; 15(5):1722-9. PubMed ID: 9164178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]